Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Reuters

2025/06/04

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase (FASN) inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462984-en) on June 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540053848"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540053848\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540053848?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540053848","market":"us","top_or_hot":-1,"title":"Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a>, a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase (FASN) inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462984-en) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a>, a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase (FASN) inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462984-en) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMT","symbol_name":"Sagimet Biosciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9NgkYx:1","article_id":"2540053848","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540053848","pubTimestamp":1749027616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase  inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGMT":"Sagimet Biosciences Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK1515":"抗疫概念","BK1161":"生物科技","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","BK1574":"生物医药B类股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","01672":"歌礼制药-B","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Sagimet Biosciences宣布Denifanstat治疗中重度痤疮的3期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":0.9,"01672":0.9,"NDAQ":0.9},"content_text":"Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne\n    \n\nSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase (FASN) inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462984-en) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}